GLP-1 patient assistance: every cost-reduction pathway available in 2026
Two manufacturer programs give a GLP-1 away free, and both cover a diabetes drug rather than a weight-loss one. A copay card takes insured patients to $25 a month. Below those sit 340B clinics, compounding and two free databases.
Novo Nordisk's Patient Assistance Program covers Ozempic. Lilly Cares covers Trulicity. Wegovy, Saxenda, Zepbound and Mounjaro are on neither company's published list, so there is no free route to any of them. If you have commercial insurance, a copay card drops you to $25 a month. Every manufacturer program, with who qualifies and what we read.
Some links here earn us a commission. Assistance lists and prices checked Monday, August 31, 2026.
Every path, and what it asks for
| Path | What you pay | What it asks for |
|---|---|---|
| Novo Nordisk PAP | Free Ozempic. Not Wegovy. | Uninsured or on Medicare, income at or below 200% of the federal poverty level, US citizen or legal resident. Approval runs 12 months. |
| Lilly Cares | Free Trulicity. Not Zepbound or Mounjaro. | Income at or below 300% of the federal poverty level. Free for up to 12 months. Apply at lillycares.com. |
| Manufacturer copay card | As low as $25/mo | Commercial insurance only. The Wegovy card takes up to $100 off a month. The Zepbound card is $25 for a 1, 2 or 3-month prescription, capped at $1,300 a year. No Medicare, Medicaid, VA or TRICARE. |
| NovoCare or LillyDirect direct | Wegovy $149 to $399/mo; Zepbound $299 to $449/mo | No insurance needed, just a telehealth prescription. Zepbound ships as vials or the KwikPen at the same price. |
| 340B clinic | Often 50 to 80% off retail | Care at a participating FQHC, usually under 200% of the poverty line. Find one in the HRSA 340B database. Longer waits, less dose flexibility. |
| Compounded semaglutide | $99 to $249/mo (tirzepatide $199 to $349) | A prescription. Not FDA-approved. 503A pharmacies compound under a personalized-formulation rule since the FDA ended the semaglutide shortage in February 2025. |
HSA and FSA money stretches further
GLP-1 prescribed for an FDA-approved indication (weight management, type 2 diabetes, cardiovascular risk, obstructive sleep apnea, MASH) is an eligible HSA and FSA expense. Off-label uses like PCOS usually qualify too, but check with your plan administrator. Paying with pre-tax dollars works out to roughly a 25 to 37 percent discount, so on a high-deductible plan it often beats running a prior authorization.
State programs
Several states run their own pharmaceutical assistance for Medicare-eligible residents 65 and older at set income limits: New York's EPIC, New Jersey's PAAD and Senior Gold, Pennsylvania's PACE and PACENET. Search "[your state] pharmaceutical assistance" or the National Conference of State Legislatures database.
The realistic floor
If nothing above fits, the cheapest cash path in 2026 is about $99 a month for compounded oral semaglutide (Strut Health, whose injectable route starts at $149) or $178 a month flat for compounded injectable semaglutide (Mochi).
Find every program you qualify for
Two free tools list them all. Patient Advocate Foundation (patientadvocate.org) assigns a case manager to help you work through the paperwork. NeedyMeds (needymeds.org) runs a searchable database of assistance programs and copay cards. Type in "semaglutide" or "tirzepatide" and read what each one asks for.
The cheapest cash route we verify is compounded semaglutide. See today's price and the full score on the Strut Health review page, or the ranked under-$150 list.
This week's best deals
Compare these programs
